Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

VK2735 is a wholly owned dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose dependent insulinotropic polypeptide, or GIP receptor, for the potential treatment of ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Reasons to buy Viking Therapeutics now It's hard to overstate the commercial success of drugs that reduce appetites by acting on glucagon-like peptide ... tentatively named VK2735, reduced obesity ...